- Report
- August 2025
- 182 Pages
Global
From €3508EUR$3,939USD£3,035GBP
- Report
- August 2025
- 182 Pages
Global
From €3158EUR$3,545USD£2,731GBP
€3508EUR$3,939USD£3,035GBP
- Report
- May 2025
- 198 Pages
Global
From €3158EUR$3,545USD£2,731GBP
€3508EUR$3,939USD£3,035GBP
- Report
- April 2025
- 250 Pages
Global
From €3999EUR$4,490USD£3,459GBP
- Report
- April 2025
- 175 Pages
Global
From €3999EUR$4,490USD£3,459GBP
- Report
- August 2025
- 182 Pages
Global
From €5210EUR$5,850USD£4,507GBP
- Report
- April 2025
- 175 Pages
Global
From €3999EUR$4,490USD£3,459GBP
- Report
- June 2025
- 150 Pages
Global
From €2404EUR$2,699USD£2,079GBP
- Report
- October 2022
- 270 Pages
Global
From €2672EUR$3,000USD£2,311GBP
€3340EUR$3,750USD£2,889GBP
- Report
- August 2022
- 118 Pages
Global
From €4008EUR$4,500USD£3,467GBP
- Report
- February 2022
- 210 Pages
Global
From €6680EUR$7,500USD£5,778GBP
- Report
- May 2024
- 128 Pages
Global
From €5788EUR$6,499USD£5,007GBP
- Report
- May 2024
- 131 Pages
Global
From €5788EUR$6,499USD£5,007GBP
- Report
- May 2024
- 139 Pages
Global
From €5788EUR$6,499USD£5,007GBP
- Report
- October 2023
- 145 Pages
Global
From €2806EUR$3,150USD£2,427GBP
- Report
- July 2024
- 231 Pages
Global
From €7081EUR$7,950USD£6,125GBP
- Report
- August 2022
- 111 Pages
Global
From €4231EUR$4,750USD£3,659GBP
- Report
- June 2022
- 120 Pages
Global
From €4231EUR$4,750USD£3,659GBP
- Report
- April 2023
- 160 Pages
Global
From €4408EUR$4,949USD£3,813GBP
- Report
- July 2024
- 200 Pages
Global
From €4408EUR$4,949USD£3,813GBP

Ixekizumab is a monoclonal antibody used to treat immune disorders. It is a type of biologic drug, which is a medication derived from living cells. It works by blocking the action of a protein called interleukin-17A (IL-17A), which is involved in inflammation. Ixekizumab is used to treat psoriasis, an autoimmune disorder that causes red, scaly patches on the skin, and psoriatic arthritis, a type of arthritis that affects people with psoriasis. It is also used to treat ankylosing spondylitis, a type of arthritis that affects the spine.
Ixekizumab is administered as an injection under the skin. It is available in both brand-name and generic forms. It is typically used in combination with other medications, such as methotrexate or corticosteroids.
Ixekizumab is manufactured by several companies, including Eli Lilly, Amgen, and Novartis. It is also available as a generic drug from several generic drug manufacturers. Show Less Read more